We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Cerep Grants BioPrint® Access to AstraZeneca

Cerep Grants BioPrint® Access to AstraZeneca

Cerep Grants BioPrint® Access to AstraZeneca

Cerep Grants BioPrint® Access to AstraZeneca

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cerep Grants BioPrint® Access to AstraZeneca"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cerep has announced that AstraZeneca has acquired a license to Cerep's proprietary BioPrint® database.

Through this alliance, AstraZeneca will have non-exclusive access to physicochemical, pharmacological and clinical data on BioPrint® compounds as well as to BioPrint® informatics tools to support internal drug discovery and development.

Payment of the license fee has been recognized upon acceptance of the data and IT tools delivered by Cerep in the first quarter 2006.

"We are very happy to announce this alliance with AstraZeneca," commented Mark Crawford, Executive Vice President for Cerep.

"BioPrint® has been established in the industry as an extremely useful tool to support drug discovery and drug development."

"We are particularly proud to have the value of BioPrint® recognized by AstraZeneca."

"We believe that database-supported pharmaco-informatics can play an important role in expediting drug discovery. We have been pleased with Cerep's BioPrint® database and we look forward to implementing this tool at AstraZeneca," commented Tim Hammond, Vice President of Safety Assessment UK, for AstraZeneca.